@article{ecb54381b5ac420689649e8620b5e75c,
title = "Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic",
keywords = "Betacoronavirus, Clinical Trials as Topic, Coronavirus Infections/complications, Disease Management, Disease Susceptibility, Humans, Immunoglobulins, Intravenous/therapeutic use, Immunologic Factors/therapeutic use, Immunosuppressive Agents/therapeutic use, Immunotherapy, Lambert-Eaton Myasthenic Syndrome/complications, Myasthenia Gravis/complications, Pandemics, Plasma Exchange, Pneumonia, Viral/complications, Vaccines, COVID-19, SARS-CoV-2",
author = "Saiju Jacob and Srikanth Muppidi and Amanda Guidon and Jeffrey Guptill and Michael Hehir and Howard, {James F} and Isabel Illa and Renato Mantegazza and Hiroyuki Murai and Kimiaki Utsugisawa and John Vissing and Heinz Wiendl and Nowak, {Richard J} and {International MG/COVID-19 Working Group}",
year = "2020",
month = may,
day = "15",
doi = "10.1016/j.jns.2020.116803",
language = "English",
volume = "412",
pages = "116803",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier BV",
}